Wilson Therapeutics Appoints Anders Martin-Löf as Chief Financial Officer
STOCKHOLM, November 2, 2015 (PR NEWSWIRE) – Wilson Therapeutics AB, a privatelyheld
biopharmaceutical company, today announced the appointment of Anders Martin-Löf as
Chief Financial Officer (CFO). Mr. Martin-Löf will report to CEO Jonas Hansson, and will join
the company’s management team.
“We are pleased to welcome Anders to the team,” said Jonas Hansson. “His leadership
experience and extensive expertise within the life sciences industry will be tremendous
helpful to Wilson as we continue our path forward and pursue our goal to bring new
treatments to patients with Wilson’s Disease.”
Mr. Martin-Löf has more than 15 years’ experience in the life science sector and has held a
number of management positions in finance, investor relations and business development.
Most recently, he served as CFO of Extenda, a privately-held software company. Before
joining Extenda, he was the CFO of RaySearch Laboratories AB, a medical technology
company that develops advanced software solutions for radiation therapy of cancer and is
listed on NASDAQ OMX Stockholm.
Prior to joining RaySearch, Mr. Martin-Löf served as Director of Investor Relations and held
various business development positions for the biotech company Biovitrum (SOBI). Before
that, he was a management consultant at the Boston Consulting Group, Cell Network and cofounder
and CEO of ScienceCap, a consulting firm focused on small-cap companies in the
biotech and medtech sectors.
Anders Martin-Löf holds a M.Sc. in Engineering Physics from the Royal Institute of Technology
and a B.Sc in Business Administration and Economics from Stockholm University.
About Wilson’s Disease
Wilson’s Disease is a rare autosomal recessive disorder caused by mutations in the ATP7B
gene, resulting in deficient production of the copper-transporter ATPase-2. Deficient or absent
production of ATPase-2 leads to impaired incorporation of Cu into ceruloplasmin and
impairment of biliary Cu excretion, which allows copper to accumulate in the body. The buildup
of copper in liver, brain, kidneys and other tissues of Wilson’s Disease patients produces
significant organ damage and dysfunction. Untreated or inadequately treated Wilson’s Disease
can result in brain damage, liver failure and death. The overall prevalence of Wilson’s Disease
is estimated to be 1-2 in 30,000 individuals.
About Wilson Therapeutics
Wilson Therapeutics is a privately-held biopharmaceutical company focused on improving the
lives of patients with Wilson’s Disease through the development of new treatment options and
increased awareness and education. The Company’s lead product candidate, WTX101, is
currently in clinical development as a treatment for Wilson’s Disease. Investors include
Abingworth, HealthCap, MVM Life Science Partners and NeoMed.
Spark BioComm LLC
Tel: + 1 650 739 9952
Spurce: Wilson Therapeutics